张俊亮， 曾其毅（综述）， 钱新华（审校）. 脓毒症辅助治疗的新进展[J]. 中国急救医学, 2016, 36(4): 316-319.
ZHANG Jun-liang, ZENG Qi-yi, QIAN Xin-hua. New development of the adjuvant treament for sepsis. Chinese Journal of Critical Care Medicine, 2016, 36(4): 316-319.
[1] Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012[J]. Crit Care Med, 2013,41（2）:580-637.
[2] Martin GS, Mannino DM, Eaton S, et al. The epidemiology of sepsis in the United States from 1979 through
2000[J]. N Engl J Med,2003,348（16）:1546-1554.
[3] Kabudula CW, Tollman S, Mee P, et al. Two decades of mortality change in rural northeast South Africa[J]. Global Health Action,2014,7:25596.
[4] Levinson AT, Casserly BP, Levy MM. Reducing mortality in severe sepsis and septic shock[J]. Semin Respir
Crit Care Med, 2011,32（2）:195-205.
[5] 商娜,周荣斌.脓毒症流行病学研究[J].中国急救医学,2013，33（1）:8-12.
[6] Angus DC, van der Poll T. Severe sepsis and septic shock[J]. N Engl J Med, 2013,369（9）:840-851.
[7] 穆雪鹍, 傅应云, 韩雪梅, 等.脓毒症患者免疫失衡与疾病严重程度的关系[J].中国急救医学，2012，32（2）:120-123.
[8] Boomer JS, To K, Chang KC, et al. Immunosuppression in patients who die of sepsis and multiple organ
failure[J]. JAMA, 2011,306（23）:2594-2605.
[9] 郭剑颖.脓毒症的免疫调理治疗[J].中国急救医学，2012,32（6）:546-549.
[10] Minneci PC, Deans KJ, Banks SM, et al. Meta-analysis: the effect of steroids on survival and shock
during sepsis depends on the dose[J]. Ann Intern Med, 2004,141（1）:47-56.
[11] Leentjens J, Kox M, van der Hoeven JG, et al. Immunotherapy for the adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm change[J]. Am J Respir Crit Care Med, 2013,
187（12）:1287-1293.
[12] Docke WD, Randow F, Syrbe U, et al. Monocyte deactivation in septic patients: restoration by IFN- gamma
treatment[J]. Nat Med,1997,3（6）:678-681.
[13] Bo L, Wang F, Zhu J, et al. Granulocyte-colony stimulating factor（G- CSF）and granulocyte- macrophage
colony stimulating factor（GM-CSF）for sepsis: a meta-analysis[J]. Crit Care, 2011,15（1）:R58.
[14] Bassir SH, Wisitrasameewong W, Raanan J, et al. Potential for stem cell- based periodontal therapy[J].
J Cell Physiol, 2016,231（1）:50-61.
[15] Douglas JJ, Tsang JL, Walley KR. Sepsis and the innate- like response[J]. Intens Care Med, 2014,
40（2）:249-251.
[16] Kjer-Nielsen L, Patel O, Corbett AJ, et al. MR1 presents microbial vitamin B metabolites to MAIT cells[J]. Nature, 2012,491（7426）:717-723.
[17] Grimaldi D, Le Bourhis L, Sauneuf B, et al. Specific MAIT cell behaviour among innate- like T
lymphocytes in critically ill patients with severe infections[J]. Intens Care Med, 2014,40（2）:192-201.
[18] Wakao H, Yoshikiyo K, Koshimizu U, et al. Expansion of functional human mucosal-associated invariant T
cells via reprogramming to pluripotency and redifferentiation[J]. Cell Stem Cell, 2013,12（5）:546-558.
[19] Wannemuehler TJ, Manukyan MC, Brewster BD, et al. Advances in mesenchymal stem cell research in sepsis[J]. J Surg Res, 2012,173（1）:113-126.
[20] Mei SHJ, Haitsma JJ, Dos Santos CC, et al. Mesenchymal stem cells reduce inflammation while enhancing
bacterial clearance and improving survival in sepsis[J]. Am J Respir Crit Care Med, 2010,182（8）:1047-1057.
[21] Krasnodembskaya A, Samarani G, Song YL, et al. Human mesen⁃chymal stem cells reduce mortality and
bacteremia in gram-negative sepsis in mice in part by enhancing the phagocytic activity of blood monocytes[J]. Am J Physiol-Lung C, 2012,302（10）:L1003-L1013.
[22] Kimbrel EA, Kouris NA, Yavanian GJ, et al. Mesenchymal stem cell population derived from human
pluripotent stem cells displays potent immunomodulatory and therapeutic properties[J]. Stem Cells Dev,
2014,23（14）:1611-1624.
[23] Spite M, Norling LV, Summers L, et al. Resolvin D2 is a potent regulator of leukocytes and controls
microbial sepsis[J]. Nature,2009,461（7268）:1287-U125.
[24] Ueda T, Fukunaga K, Seki H, et al. Combination therapy of 15-epilipoxin A4 with antibiotics protects
mice from Escherichia coli-induced sepsis[J]. Crit Care Med, 2014,42（4）:e288-95.
[25] Gong J, Guo S, Li HB, et al. BML-111, a lipoxin receptor agonist,protects haemorrhagic shock- induced
acute lung injury in rats[J].Resuscitation, 2012,83（7）:907-912.
[26] Li H, Wu Z, Feng D, et al. BML-111, a lipoxin receptor agonist, attenuates ventilator-induced lung
injury in rats[J]. Shock, 2014,41（4）:311-316.
[27] Jones AE, Puskarich MA. The Surviving Sepsis Campaign guidelines 2012: update for emergency physicians[J]. Ann Emerg Med,2014,63（1）:35-47.
[28] Lemarie J, Blet A, Bouazza Y, et al. Dexamethasone and recombinant human activated protein C improve
myocardial function and efficiency during experimental septic shock[J]. Shock, 2014,41（6）:522-527.
[29] Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C
for severe sepsis[J]. N Engl J Med, 2001,344（10）:699-709.
[30] Abraham E, Laterre PF, Garg R, et al. Drotrecogin alfa（activated）for adults with severe sepsis and a
low risk of death[J]. N Engl J Med, 2005,353（13）:1332-1341.
[31] Nadel S, Goldstein B, Williams MD, et al. Drotrecogin alfa（activated）in children with severe sepsis:
a multicentre phase Ⅲ randomised controlled trial[J]. Lancet, 2007,369（9564）:836-843.
[32] Ranieri VM, Thompson BT, Barie PS, et al. Drotrecogin alfa（activated）in adults with septic shock[J].
N Engl J Med, 2012,366（22）:2055-2064.
[33] Opal SM, Dellinger RP, Vincent JL, et al. The next generation of sepsis clinical trial designs: what is
next after the demise of recombinant human activated protein C[J]. Crit Care Med, 2014,42（7）:1714-1721.
